Modulation of the action of insulin by angiotensin-(1-7)

Clinical Science

Volumn 126, Issue 9, 2014, Pages 613-630

  Dominici, Fernando P ^a   Burghi, Valeria ^a   Muñoz, Marina C ^a   Giani, Jorge F ^b  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Angiotensin (1 7); Angiotensin converting enzyme 2 (ACE2); Insulin; Mas receptor; Renin angiotensin system (RAS)

Indexed keywords

ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; PEPTIDE FRAGMENTS; PEPTIDYL-DIPEPTIDASE A; PROTO-ONCOGENE PROTEINS; RECEPTORS, G-PROTEIN-COUPLED; RENIN-ANGIOTENSIN SYSTEM; SIGNAL TRANSDUCTION;

EID: 84894049935     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20130333     Document Type: Review

References (192)

1. Scully, T. (2012) Diabetes in numbers. Nature 485, S2-S3.
2. Grundy, S. M., Brewer, Jr, H. B., Cleeman, J. I., Smith, Jr, S. C. and Lenfant, C. (2004) Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109, 433-438.
3. Biddinger, S. B. and Kahn, C. R. (2006) From mice to men: insights into the insulin resistance syndromes. Annu. Rev. Physiol. 68, 123-158.
4. Reaven, G. M. (2011) The metabolic syndrome: time to get off the merry-go-round? J. Intern. Med. 269, 127-136.
5. DeFronzo, R. A. (1997) Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidaemia and atherosclerosis. Neth. J. Med. 50, 191-197.
6. Matthaei, S., Stumvoll, M., Kellerer, M. and Haring, H. U. (2000) Pathophysiology and pharmacological treatment of insulin resistance. Endocr. Rev. 21, 585-618.
7. Rask-Madsen, C. and Kahn, C. R. (2012) Tissue-specific insulin signaling, metabolic syndrome, and cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 32, 2052-2059.
8. Velloso, L. A., Folli, F., Sun, X. J., White, M. F., Saad, M. J. and Kahn, C. R. (1996) Cross-talk between the insulin and angiotensin signaling systems. Proc. Natl. Acad. Sci. U.S.A. 93, 12490-12495.
9. Folli, F., Kahn, C. R., Hansen, H., Bouchie, J. L. and Feener, E. P. (1997) Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk. J. Clin. Invest. 100, 2158-2169.
10. Calegari, V. C., Alves, M., Picardi, P. K., Inoue, R. Y., Franchini, K. G., Saad, M. J. and Velloso, L. A. (2003) Suppressor of cytokine signaling-3 provides a novel interface in the cross-talk between angiotensin II and insulin signaling systems. Endocrinology 146, 579-588.
11. Carvalheira, J. B., Calegari, V. C., Zecchin, H. G., Nadruz, Jr, W., Guimaraes, R. B., Ribeiro, E. B., Franchini, K. G., Velloso, L. A. and Saad, M. J. (2005) The cross-talk between angiotensin and insulin differentially affects phosphatidylinositol 3-kinase and mitogen-activated protein kinase-mediated signaling in rat heart: implications for insulin resistance. Endocrinology 144, 5604-5614.
12. Velloso, L. A., Folli, F., Perego, L. and Saad, M. J. (2006) The multi-faceted cross-talk between the insulin and angiotensin II signaling systems. Diabetes Metab. Res. Rev. 22, 98-107.
13. Muscogiuri, G., Chavez, A. O., Gastaldelli, A., Perego, L., Tripathy, D., Saad, M. J., Velloso, L. and Folli, F. (2008) The crosstalk between insulin and renin-angiotensin-aldosterone signaling systems and its effect on glucose metabolism and diabetes prevention. Curr. Vasc. Pharmacol. 6, 301-312.
14. Rizza, R., Mandarino, L. J. and Gerich, J. E. (1982) Cortisol-induced insulin resistance in man: impaired suppression of glucose production and stimulation of glucose utilization due to a postreceptor defect of insulin action. J. Clin. Endocrinol. Metab. 54, 131-138.
15. Deibert, D. C. and DeFronzo, R. A. (1980) Epinephrine-induced insulin resistance in man. J. Clin. Invest. 65, 717-721.
16. Houssay, B. A. (1936) The hypophysis and metabolism. N. Engl. J. Med. 214, 961-986.
17. Coppari, R. and Bjørbæk, C. (2012) Leptin revisited: its mechanism of action and potential for treating diabetes. Nat. Rev. Drug. Discov. 11, 692-708.
18. Yamauchi, T., Kamon, J., Waki, H., Terauchi, Y., Kubota, N., Hara, K., Mori, Y., Ide, T., Murakami, K., Tsuboyama-Kasaoka, N. et al. (2001) The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med. 7, 941-946.
19. Henriksen, E. J. (2007) Improvement of insulin sensitivity by antagonism of the renin-angiotensin system. Am. J. Physiol. Regul. Integr. Comp. Physiol. 293, R974-R980.
20. Perkins, J. M. and Davis, S. N. (2008) The renin-angiotensin aldosterone system: a pivotal role in insulin sensitivity and glycemic control. Curr. Opin. Endocrinol. Diabetes Obes. 15, 147-152.
21. Putnam, K., Shoemaker, R., Yiannikouris, F. and Cassis, L. A. (2012) The renin-angiotensin system: a target of and contributor to dyslipidemias, altered glucose homeostasis, and hypertension of the metabolic syndrome Am. J. Physiol. Heart Circ. Physiol. 302, H1219-H1230.
22. Rao, R. H. (1994) Effects of angiotensin II on insulin sensitivity and fasting glucose metabolism in rats. Am. J. Hypertens. 7, 655-660.
23. Richey, J. M., Ader, M., Moore, D. and Bergman, R. N. (1999) Angiotensin II induces insulin resistance independent of changes in interstitial insulin. Am. J. Physiol. 277, E920-E926.
24. 616 in human umbilical vein endothelial cells. Circ. Res. 94, 1211-1218.
25. Kim, J. A., Jang, H. J., Martinez-Lemus, L. A. and Sowers, J. R. (2012) Activation of mTOR/p70S6 kinase by ANG II inhibits insulin-stimulated endothelial nitric oxide synthase and vasodilation. Am. J. Physiol. Endocrinol. Metab. 302, E201-E208.
26. Scheen, A. J. (2004) Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. A meta-analysis of randomized clinical trials. Diabetes Metab. 30, 487-496.
27. Jandeleit-Dahm, K. A., Tikellis, C., Reid, C. M, Johnston, C. I. and Cooper, ME. (2005) Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes J. Hypertens. 23, 463-473.
28. Prabhakar, S. (2013) Inhibition of renin-angiotensin system: implications for diabetes control and prevention J. Invest. Med. 61, 551-557.
29. Furuhashi, M., Ura, N., Takizawa, H., Yoshida, D., Moniwa, N., Murakami, H., Higashiura, K. and Shimamoto, K. (2004) Blockade of the renin-angiotensin system decreases adipocyte size with improvement in insulin sensitivity. J. Hypertens. 22, 1977-1982.
30. Henriksen, E. J., Jacob, S., Kinnick, T. R., Teachey, M. K. and Krekler, M. (2001) Selective angiotensin II receptor antagonism reduces insulin resistance in obese Zucker rats. Hypertension 38, 884-890.
31. Reference deleted
32. Higashiura, K., Ura, N., Takada, T., Li, Y., Torii, T., Togashi, N., Takada, M., Takizawa, H. and Shimamoto, K. (2000) The effects of an angiotensin-converting enzyme inhibitor and an angiotensin II receptor antagonist on insulin resistance in fructose-fed rats. Am. J. Hypertens. 13, 290-297.
33. Muñoz, M. C., Argentino, D. P., Dominici, F. P., Turyn, D. and Toblli, J. E. (2006) Irbersartan restores the in vivo insulin signaling pathway leading to Akt activation in obese Zucker rats. J. Hypertens. 24, 1607-1617.
34. Nawano, M., Anai, M., Funaki, M., Kobayashi, H., Kanda, A., Fukushima, Y., Inukai, K., Ogihara, T., Sakoda, H., Onishi, Y. et al. (1999) Imidapril, an angiotensin-converting enzyme inhibitor, improves insulin sensitivity by enhancing signal transduction via insulin receptor substrate proteins and improving vascular resistance in the Zucker fatty rat. Metabolism 48, 1248-1255.
35. Carvalho, C. R., Thirone, A. C., Gontijo, J. A., Velloso, L. A. and Saad, M. J. (1997) Effect of captopril, losartan, and bradykinin on early steps of insulin action. Diabetes 46, 1950-1957.
36. Iusuf, D., Henning, R. H., van Gilst, W. H. and Roks, A. J. (2008) Angiotensin-(1-7): pharmacological properties and pharmacotherapeutic perspectives. Eur. J. Pharmacol. 585, 303-312.
37. Ferrario, C. M., Ahmad, S., Joyner, J. and Varagic, J. (2010) Advances in the renin angiotensin system focus on angiotensin-converting enzyme 2 and angiotensin-(1-7). Adv. Pharmacol. 59, 197-233.
38. Zimmerman, D. and Burns, K. D. (2012) Angiotensin-(1-7) in kidney disease: a review of the controversies. Clin. Sci. 123, 333-346.
39. Passos-Silva, D. G., Verano-Braga, T. and Santos, RA. (2013) Angiotensin-(1-7): beyond the cardio-renal actions. Clin. Sci. 124, 443-456.
40. Iyer, S. N., Ferrario, C. M. and Chappell, M. C. (1988) Angiotensin-(1-7) contributes to the antihypertensive effects of blockade of the renin-angiotensin system. Hypertension 31, 356-361.
41. Yamada, K., Iyer, S. N., Chappell, M. C., Brosnihan, K. B., Fukuhara, M. and Ferrario, C. M. (1999) Differential response of angiotensin peptides in the urine of hypertensive animals. Regul. Pept. 80, 57-66.
42. Chappell, M. C., Gomez, M. N., Pirro, N. T. and Ferrario, C. M. (2000) Release of angiotensin-(1-7) from the rat hindlimb: influence of angiotensin-converting enzyme inhibition. Hypertension 35, 348-352.
43. Nussberger, J., Brunner, D. B., Nyfeler, J. A., Linder, L. and Brunner, H. R. (2001) Measurement of immunoreactive angiotensin-(1-7) heptapeptide in human blood. Clin. Chem. 47, 726-729.
44. Hao, P. P., Chen, Y. G., Liu, Y. P., Zhang, M. X., Yang, J. M., Gao, F., Zhang, Y. and Zhang, C. (2013) Association of plasma angiotensin-(1-7) level and left ventricular function in patients with type 2 diabetes mellitus. PLoS ONE 8, e62788.
45. Nogueira, A. I., Souza, Santos, R. A., Simões, E., Silva, A. C., Cabral, A. C., Vieira, R. L., Drumond, T. C., Machado, L. J., Freire, C. M. and Ribeiro-Oliveira, Jr, A. (2007) The pregnancy-induced increase of plasma angiotensin-(1-7) is blunted in gestational diabetes. Regul. Pept. 141, 55-60.
46. Neves, L. A., Stovall, K., Joyner, J., Valdés, G., Gallagher, P. E., Ferrario, C. M., Merrill, D. C. and Brosnihan, K. B. (2008) ACE2 and ANG-(1-7) in the rat uterus during early and late gestation. Am. J. Physiol. Regul. Integr. Comp. Physiol. 294, R151-R161.
47. Chhabra, K. H., Chodavarapu, H. and Lazartigues, E. (2013) Angiotensin converting enzyme 2: A new important player in the regulation of glycemia. IUBMB Life 65, 731-738.
48. Gupte, M., Thatcher, S. E., Boustany-Kari, C. M., Shoemaker, R., Yiannikouris, F., Zhang, X., Karounos, M. and Cassis, L. A. (2012) Angiotensin converting enzyme 2 contributes to sex differences in the development of obesity hypertension in C57BL/6 mice. Arterioscler. Thromb. Vasc. Biol. 32, 1392-1399.
49. Hubbard, S. R. (2013) The insulin receptor: both a prototypical and atypical receptor tyrosine kinase. Cold Spring Harb. Perspect. Biol. 5, a008946.
50. Taniguchi, C. M., Emanuelli, B. and Kahn, C. R. (2006) Critical nodes in signalling pathways: insights into insulin action. Nat. Rev. Mol. Cell Biol. 7, 85-96.
51. Copps, K. D. and White, M. F. (2012) Regulation of insulin sensitivity by serine/threonine phosphorylation of insulin receptor substrate proteins IRS1 and IRS2. Diabetologia 55, 2565-2582.
52. Giorgetti-Peraldi, S., Peyrade, F., Baron, V. and Van Obberghen, E. (1995) Involvement of Janus kinases in the insulin signaling pathway. Eur. J. Biochem. 234, 656-660.
53. Cantley, L. C. (2002) The phosphoinositide 3-kinase pathway. Science 296, 1655-1657.
54. Manning, B. D. and Cantley, L. C. (2007) AKT/PKB signaling: navigating downstream. Cell 129, 1261-1274.
55. Vasudevan, K. M. and Garraway, L. A. (2010) AKT signaling in physiology and disease. Curr. Top. Microbiol. Immunol. 347, 105-133.
56. Maegawa., H., Kashiwagi., A., Fujita, T., Ugi, S., Hasegawa, M., Obata, T., Nishio, Y., Kojima, H., Hidaka, H. and Kikkawa, R. (1996) SHPTP2 serves adapter protein linking between Janus kinase 2 and insulin receptor substrates. Biochem. Biophys. Res. Commun. 228, 122-127.
57. Chen, J., Sadowski, H. B., Kohanski, R. A. and Wang, L. H. (1997) Stat5 is a physiological substrate of the insulin receptor. Proc. Natl. Acad. Sci. U.S.A. 94, 2295-2300.
58. Gual, P., Baron, V., Lequoy, V. and Van Obberghen, E. (1998) Interaction of Janus kinases JAK-1 and JAK-2 with the insulin receptor and the insulin-like growth factor-1 receptor. Endocrinology 139, 884-893.
59. Campos, S. P., Wang, Y. and Baumann, H. (1996) Insulin modulates STAT3 protein activation and gene transcription in hepatic cells. J. Biol. Chem. 271, 24418-24424.
60. Sawka-Verhelle, D., Tartare-Deckert, S., Decaux, J. F., Girard, J. and Van Obberghen, E. (2000) Stat 5B, activated by insulin in a Jak-independent fashion, plays a role in glucokinase gene transcription. Endocrinology 141, 1977-1988.
61. Saad, M. J. A., Carvalho, C. R. O., Thirone, A. C. P. and Velloso, L. A. (1996) Insulin induces tyrosine phosphorylation of JAK2 in insulin-sensitive tissues of the intact rat. J. Biol. Chem. 271, 22100-22104.
62. Velloso, L. A., Carvalho, C. R., Rojas, F. A., Folli, F. and Saad, M. J. (1998) Insulin signalling in heart involves insulin receptor substrates-1 and -2, activation of phosphatidylinositol 3-kinase and the JAK 2-growth related pathway. Cardiovasc. Res. 40, 96-102.
63. Thirone, A. C., JeBailey, L., Bilan, P. J. and Klip, A. (2006) Opposite effect of JAK2 on insulin-dependent activation of mitogen-activated protein kinases and Akt in muscle cells: possible target to ameliorate insulin resistance. Diabetes 55, 942-951.
64. Avruch, J. (2007) MAP kinase pathways: the first twenty years. Biochem. Biophys. Acta 1773, 1150-1160.
65. Siddle, K. (2011) Signalling by insulin and IGF receptors: supporting acts and new players. J. Mol. Endocrinol. 47, R1-R10.
66. Youngren, J. F. (2007) Regulation of insulin receptor function. Cell. Mol. Life Sci. 64, 873-891.
67. Feener, E. P., Backer, J. M., King, G. L., Wilden, P. A., Sun, X. J., Kahn, C. R. and White, M. F. (1993) Insulin stimulates serine and tyrosine phosphorylation in the juxtamembrane region of the insulin receptor. J. Biol. Chem. 268, 11256-11264.
68. Coba, M. P., Muñoz, M. C., Dominici, F. P., Toblli, J. E., Pena, C., Bartke, A. and Turyn, D. (2004) Increased in vivo phosphorylation of insulin receptor at serine 994 in the liver of obese insulin-resistant Zucker rats. J. Endocrinol. 182, 433-444.
69. Liu, F. and Roth, R. A. (1994) Identification of serines-1035/1037 in the kinase domain of the insulin receptor as protein kinase C α mediated phosphorylation sites. FEBS Lett. 352, 389-392.
70. Ahn, J., Donner, D. B. and Rosen, O. M. (1993) Interaction of the human insulin receptor tyrosine kinase from the baculo-virus expression system with protein kinase C in a cell-free system. J. Biol. Chem. 268, 7571-7576.
71. Al Hasani, H., Eisermann, B., Tennagels, N., Magg, C., Passlack, W., Koenen, M., Muller-Wieland, D., Meyer, H. E. and Klein, H. W. (1997) Identification of Ser-1275 and Ser-1309 as autophosphorylation sites of the insulin receptor. FEBS Lett. 400, 65-70.
72. Schmitz-Peiffer, C. (2002) Protein kinase C and lipid-induced insulin resistance in skeletal muscle. Ann. N.Y. Acad. Sci. 967, 146-157.
73. Itani, S. I., Zhou, Q., Pories, W. J., MacDonald, K. G. and Dohm, G. L. (2000) Involvement of protein kinase C in human skeletal muscle insulin resistance and obesity. Diabetes 49, 1353-1358.
74. Cortright, R. N., Azevedo, Jr, J. L., Zhou, Q., Sinha, M., Pories, W. J., Itani, S. I. and Dohm, G. L. (2000) Protein kinase C modulates insulin action in human skeletal muscle. Am. J. Physiol. Endocrinol. Metab. 278, E553-E562.
75. Pillay, T. S., Xiao, S., Keranen, L. and Olefsky, J. M. (2004) Regulation of the insulin receptor by protein kinase C isoenzymes: preferential interaction with β isoenzymes and interaction with the catalytic domain of βII. Cell. Signal. 16, 97-104.
76. Nguyen, M. T., Satoh, H., Favelyukis, S., Babendure, J. L., Imamura, T., Sbodio, J. I., Zalevsky, J., Dahiyat, B. I., Chi, N. W. and Olefsky, J. M. (2005) JNK and tumor necrosis factor-α mediate free fatty acid-induced insulin resistance in 3T3-L1 adipocytes. J. Biol. Chem. 280, 35361-35371.
77. Muñoz, M. C., Giani, J. F., Mayer, M. A., Toblli, J. E., Turyn, D. and Dominici, F. P. (2009) TANK-binding kinase 1 mediates phosphorylation of insulin receptor at serine residue 994: a potential link between inflammation and insulin resistance. J. Endocrinol. 201, 185-197.
78. Mothe, I. and Van Obberghen, E. (1996) Phosphorylation of insulin receptor substrate-1 on multiple serine residues, 612, 632, 662, and 731, modulates insulin action. J. Biol. Chem. 271, 11222-11227.
79. 307. J. Biol. Chem. 275, 9047-9054.
80. Gao, Z., Hwang, D., Bataille, F., Lefevre, M, York, D., Quon, M. J. and Ye, J. (2002) Serine phosphorylation of insulin receptor substrate 1 by inhibitor B kinase complex. J. Biol. Chem. 277, 48115-48121.
81. Solinas, G. and Karin, M. (2010) JNK1 and IKKβ: molecular links between obesity and metabolic dysfunction. FASEB J. 24, 2596-2611.
82. 307 via distinct pathways. J. Clin. Invest. 107, 181-189.
83. 307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action. J. Biol. Chem. 277, 1531-1537.
84. Carlson, C. J., White, M. F. and Rondinone, C. M. (2004) Mammalian target of rapamycin regulates IRS-1 serine 307 phosphorylation. Biochem. Biophys. Res. Commun. 316, 533-539.
85. Giani, J. F., Mayer, M. A., Muñoz, M. C., Silberman, E., Hc̈ht, C., Taira, C., Gironacci, M. M., Turyn, D. and Dominici, F. P. (2009) Chronic infusion of angiotensin-(1-7) improves insulin resistance and hypertension induced by a high-fructose diet in rats. Am. J. Physiol. Endocrinol. Metab. 296, E262-E271.
86. 616 in human umbilical vein endothelial cells. Circ. Res. 94, 1211-1218.
87. Bouzakri, K., Roques, M., Gual, P., Espinosa, S., Guebre-Egziabher, F., Riou, J. P., Laville, M., Le Marchand-Brustel, Y., Tanti, J. F. and Vidal, H. (2003) Reduced activation of phosphatidylinositol-3 kinase and increased serine 636 phosphorylation of insulin receptor substrate-1 in primary culture of skeletal muscle cells from patients with type 2 diabetes. Diabetes 52, 1319-1325.
88. Sampaio, W. O., Souza dos Santos, R. A., Faria-Silva, R., Mata Machado, L. T., Schiffrin, E. L. and Touyz, R. M. (2007) Angiotensin-(1-7) through receptor Mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways. Hypertension 49, 185-192.
89. Giani, J. F., Gironacci, M. M., Muñoz, M. C., Peña, C., Turyn, D. and Dominici, F. P. (2007) Angiotensin-(1-7) stimulates the phosphorylation of JAK2, IRS-1 and Akt in rat heart in vivo: role of the AT1 and Mas receptors. Am. J. Physiol. Heart Circ. Physiol. 293, H1154-H1163.
90. Giani, J. F., Gironacci, M. M., Muñoz, M. C., Turyn, D. and Dominici, F. P. (2008) Angiotensin-(1-7) has a dual role on growth-promoting signalling pathways in rat heart in vivo by stimulating STAT3 and STAT5a/b phosphorylation and inhibiting angiotensin II-stimulated ERK1/2 and Rho kinase activity. Exp. Physiol. 93, 570-578.
91. Muñoz, M. C., Giani, J. F. and Dominici, F. P. (2010) Angiotensin-(1-7) stimulates the phosphorylation of Akt in rat extracardiac tissues in vivo via receptor Mas. Regul. Pept. 161, 1-7.
92. Muñoz, M. C., Giani, J. F., Burghi, V., Mayer, M. A., Carranza, A., Taira, C. A. and Dominici, F. P. (2012) The Mas receptor mediates modulation of insulin signaling by angiotensin-(1-7). Regul. Pept. 177, 1-11.
93. Verano-Braga, T., Schwämmle, V., Sylvester, M., Passos-Silva, D. G., Peluso, A. A., Etelvino, G. M., Santos, R. A. and Roepstorff, P. (2012) Time-resolved quantitative phosphoproteomics: new insights into angiotensin-(1-7) signaling networks in human endothelial cells. J. Proteome Res. 11, 3370-3381.
94. Marrero, M. B., Schieffer, B., Paxton, W. G., Heerdt, L., Berk, B. C., Delafontaine, P. and Bernstein, K. E. (1995) Direct stimulation of Jak/STAT pathway by the angiotensin II AT1 receptor. Nature 375, 247-250.
95. Kodama, H., Fukuda, K., Pan, J., Makino, S., Sano, M., Takahashi, T., Hori, S. and Ogawa, S. (1998) Biphasic activation of the JAK/STAT pathway by angiotensin II in rat cardiomyocytes. Circ. Res. 82, 244-250.
96. McWhinney, C. D., Hunt, R. A., Conrad, K. M., Dostal, D. E. and Baker, K. M. (1997) The type I angiotensin II receptor couples to Stat1 and Stat3 activation through Jak2 kinase in neonatal rat cardiac myocytes. J. Mol. Cell. Cardiol. 29, 2513-2524.
97. Guilluy, C., Brégeon, J., Toumaniantz, G., Rolli-Derkinderen, M., Retailleau, K., Loufrani, L., Henrion, D., Scalbert, E., Bril, A., Torres, R. M. et al. (2010) The Rho exchange factor Arhgef1 mediates the effects of angiotensin II on vascular tone and blood pressure. Nat. Med. 16, 183-190.
98. Banes-Berceli, A. K., Al-Azawi, H., Proctor, D., Qu, H., Femminineo, D., Hill-Pyror, C., Webb, R. C. and Brands, M. W. (2011) Angiotensin II utilizes Janus kinase 2 in hypertension, but not in the physiological control of blood pressure, during low-salt intake. Am. J. Physiol. Regul. Integr. Comp. Physiol. 301, R1169-R1176.
99. Marrero, M. B., Fulton, D., Stepp, D. and Stern, D. M. (2005) Angiotensin II-induced signaling pathways in diabetes. Curr. Diabetes Rev. 1, 197-202.
100. Saad, M. J., Velloso, L. A. and Carvalho, C. R. (1995) Angiotensin II induces tyrosine phosphorylation of insulin receptor substrate 1 and its association with phosphatidylinositol 3-kinase in rat heart. Biochem. J. 310, 741-744.
101. Ali, M. S., Schieffer, B., Delafontaine, P., Bernstein, K. E., Ling, B. N. and Marrero, M. B. (1997) Angiotensin II stimulates tyrosine phosphorylation and activation of insulin receptor substrate 1 and protein-tyrosine phosphatase 1D in vascular smooth muscle cells. J. Biol. Chem. 272, 12373-12379.
102. White, M. F. (1997) The insulin signalling system and the IRS proteins. Diabetologia 40, S2-S17.
103. Shaw, L. M. (2011) The insulin receptor substrate (IRS) proteins: at the intersection of metabolism and cancer. Cell Cycle 10, 1750-1756.
104. Bosnyak, S., Jones, E. S., Christopoulos, A., Aguilar, M. I., Thomas, W. G. and Widdop, R. E. (2011) Relative affinity of angiotensin peptides and novel ligands at AT1 and AT2 receptors. Clin. Sci. 121, 297-303.
105. Rowe, B. P., Saylor, D. L., Speth, R. C. and Absher, D. R. (1995) Angiotensin-(1-7) binding at angiotensin II receptors in the rat brain. Regul. Pept. 56, 139-146.
106. Handa, R. K., Ferrario, C. M. and Strandhoy, J. W. (1996) Renal actions of angiotensin-(1-7): in vivo and in vitro studies. Am. J. Physiol. 270, F141-F147.
107. Tallant, E. A., Lu, X., Weiss, R. B., Chappell, M. C. and Ferrario, CM. (1997) Bovine aortic endothelial cells contain an angiotensin-(1-7) receptor. Hypertension 29, 388-393.
108. Pfeilschifter, J., Huwiler, A., Merriweather, C. and Briner, V. A. (1992) Angiotensin II stimulation of phospholipase D in rat renal mesangial cells is mediated by the AT1 receptor subtype. Eur. J. Pharmacol. 225, 57-62.
109. Osei, S. Y., Ahima, R. S., Minkes, R. K., Weaver, J. P., Khosla, M. C. and Kadowitz, P. J. (1993) Differential responses to angiotensin-(1-7) in the feline mesenteric and hindquarters vascular beds. Eur. J. Pharmacol. 234, 35-42.
110. Garcia, N. H. and Garvin, J. L. (1994) Angiotensin 1-7 has a biphasic effect on fluid absorption in the proximal straight tubule. J. Am. Soc. Nephrol. 5, 1133-1138.
111. Oudot, A., Vergely, C., Ecarnot-Laubriet, A. and Rochette, L. (2005) Pharmacological concentration of angiotensin-(1-7) activates NADPH oxidase after ischemia-reperfusion in rat heart through AT1 receptor stimulation. Regul. Pept. 127, 101-110.
112. Lara, L. S., De Carvalho, T., Leã-Ferreira, L. R., Lopes, A. G. and Caruso-Neves, C. (2005) Modulation of the (Na+ +K+)ATPase activity by angiotensin-(1-7) in MDCK cells. Regul. Pept. 129, 221-226.
113. Von Bohlen, O., Halbach, U., Walther, T., Bader, M. and Albrecht, D. (2000) Interaction between Mas and the angiotensin AT1 receptor in the amygdala. J. Neurophysiol. 83, 2012-2021.
114. Kostenis, E., Milligan, G, Christopoulos, A., Sanchez-Ferrer, C. F., Heringer-Walther, S., Sexton, P. M., Gembardt, F., Kellett, E., Martini, L., Vanderheyden, P. et al. (2005) G-protein-coupled receptor Mas is a physiological antagonist of the angiotensin II type 1 receptor. Circulation 111, 1806-1813.
115. Clark, M. A., Tallant, E. A. and Diz, D. I. (2001) Downregulation of the AT1A receptor by pharmacologic concentrations of angiotensin-(1-7). J. Cardiovasc. Pharmacol. 37, 437-448.
116. Clark, M. A., Tallant, E. A., Tommasi, E., Bosch, S. and Diz, D. I. (2003) Angiotensin-(1-7) reduces renal angiotensin II receptors through a cyclooxygenase-dependent mechanism. J. Cardiovasc. Pharmacol. 41, 276-283.
117. Dias-Peixoto, M. F., Santos, R. A., Gomes, E. R., Alves, M. N., Almeida, P. W., Greco, L., Rosa, M., Fauler, B., Bader, M., Alenina, N. and Guatimosim, S. (2008) Molecular mechanisms involved in the angiotensin-(1-7)/Mas signaling pathway in cardiomyocytes. Hypertension 52, 542-548.
118. Oh, Y. B., Kim, J. H., Park, B. M., Park, B. H. and Kim, S. H. (2012) Captopril intake decreases body weight gain via angiotensin-(1-7). Peptides 37, 79-85.
119. 1 receptor signaling pathways. J. Biol. Chem. 288, 15520-15531.
120. Jarajapu, Y. P., Bhatwadekar, A. D., Caballero, S., Hazra, S., Shenoy, V., Medina, R., Kent, D., Stitt, A. W., Thut, C., Finney, E. M. et al. (2013) Activation of the ACE2/angiotensin-(1-7)/ Mas receptor axis enhances the reparative function of dysfunctional diabetic endothelial progenitors. Diabetes 62, 1258-1269.
121. + exchanger. Am. J. Physiol. Heart Circ. Physiol. 298, H1365-H1374.
122. Dominguez, V., Raimondi, C., Somanath, S., Bugliani, M., Loder, M. K., Edling, C. E., Divecha, N., da Silva-Xavier, G., Marselli, L., Persaud, S. J. et al. (2011) Class II phosphoinositide 3-kinase regulates exocytosis of insulin granules in pancreatic beta cells. J. Biol. Chem. 286, 4216-4225.
123. Falasca, M., Hughes, W. E., Dominguez, V., Sala, G., Fostira, F., Fang, M. Q., Cazzolli, R., Shepherd, P. R., James, D. E. and Maffucci, T. (2007) The role of phosphoinositide 3-kinase C2α in insulin signaling. J. Biol. Chem. 282, 28226-28236.
124. Leibiger, B., Moede, T., Uhles, S., Barker, C. J., Creveaux, M., Domin, J., Berggren, P. O. and Leibiger, I. B. (2010) Insulin-feedback via PI3K-C2α activated PKBα/Akt1 is required for glucose-stimulated insulin secretion. FASEB J. 24, 1824-1837.
125. Xu, P., Costa-Goncalves, A. C., Todiras, M., Rabelo, L. A., Sampaio, W. O., Moura, M. M., Santos, S. S., Luft, F. C., Bader, M., Gross, V. et al. (2008) Endothelial dysfunction and elevated blood pressure in MAS gene-deleted mice. Hypertension 51, 574-580.
126. Rayasam, G. V., Tulasi, V. K., Sodhi, R., Davis, J. A. and Ray, A. (2009) Glycogen synthase kinase 3: more than a namesake. Br. J. Pharmacol. 156, 885-898.
127. Sutherland, C., Leighton, I. A. and Cohen, P. (1993) Inactivation of glycogen synthase kinase-3β by phosphorylation: new kinase connections in insulin and growth-factor signalling. Biochem. J. 296, 15-19.
128. Kane, S., Sano, H., Liu, S. C., Asara, J. M., Lane, W. S., Garner, C. C. and Lienhard, G. E. (2002) A method to identify serine kinase substrates. Akt phosphorylates a novel adipocyte protein with a Rab GTPase-activating protein (GAP) domain. J. Biol. Chem. 277, 22115-22118.
129. Sano, H., Kane, S., Sano, E., Mîinea, C. P., Asara, J. M., Lane, W. S., Garner, C. W. and Lienhard, G. E. (2003) Insulin-stimulated phosphorylation of a Rab GTPase-activating protein regulates GLUT4 translocation. J. Biol. Chem. 278, 14599-14602.
130. Kramer, H. F., Witczak, C. A., Taylor, E. B., Fujii, N., Hirshman, M. F. and Goodyear, L. J. (2006) AS160 regulates insulin- and contraction-stimulated glucose uptake in mouse skeletal muscle. J. Biol. Chem. 281, 31478-31485.
131. Wang, H. Y., Ducommun, S., Quan, C., Xie, B., Li, M., Wasserman, D. H., Sakamoto, K., Mackintosh, C. and Chen, S. (2013) AS160 deficiency causes whole-body insulin resistance via composite effects in multiple tissues. Biochem. J. 449, 479-489.
132. Liu, C., Lv, X. H., Li, H. X., Cao, X., Zhang, F., Wang, L., Yu, M. and Yang, J. K. (2012) Angiotensin-(1-7) suppresses oxidative stress and improves glucose uptake via Mas receptor in adipocytes. Acta Diabetol. 49, 291-299.
133. Tirosh, A., Potashnik, R., Bashan, N. and Rudich, A. (1999) Oxidative stress disrupts insulin-induced cellular redistribution of insulin receptor substrate-1 and phosphatidylinositol 3-kinase in 3T3-L1 adipocytes. A putative cellular mechanism for impaired protein kinase B activation and GLUT4 translocation. J. Biol. Chem. 274, 10595-10602.
134. Blair, A. S., Hajduch, E., Litherland, G. J. and Hundal, H. S. (1999) A putative cellular mechanism for impaired protein kinase B activation and GLUT4 translocation. Regulation of glucose transport and glycogen synthesis in L6 muscle cells during oxidative stress. Evidence for cross-talk between the insulin and SAPK2/p38 mitogen-activated protein kinase signaling pathways. J. Biol Chem. 274, 36293-36299.
135. Accili, D. and Arden, K. C. (2004) FOXOs at the crossroads of cellular metabolism, differentiation, and transformation. Cell 117, 421-426.
136. Matsumoto, M., Han, S., Kitamura, T. and Accili, D. (2006) Dual role of transcription factor FOXO1 in controlling hepatic insulin sensitivity and lipid metabolism. J. Clin. Invest. 116, 2464-2472.
137. Puig, O. and Tjian, R. (2006) Nutrient availability and growth: regulation of insulin signaling by dFOXO/FOXO1. Cell Cycle 5, 503-505.
138. Dong, X. C., Copps, K. D., Guo, S., Li, Y., Kollipara, R., DePinho, R. A. and White, M. F. (2008) Inactivation of hepatic FOXO1 by insulin signaling is required for adaptive nutrient homeostasis and endocrine growth regulation. Cell Metab. 8, 65-76.
139. Santos, R. A. S., Ferreira, A. J., Verano-Braga, T. and Bader, M. (2013) Angiotensin-converting enzyme 2, angiotensin-(1-7) and Mas: new players of the renin-angiotensin system. J. Endocrinol. 216, R1-R17.
140. Tassone, E. J., Sciacqua, A., Andreozzi, F., Presta, I., Perticone, M., Carnevale, D., Casaburo, M., Hribal, M. L., Sesti, G. and Perticone, F. (2013) Angiotensin (1-7) counteracts the negative effect of angiotensin II on insulin signalling in HUVECs. Cardiovasc. Res. 99, 129-136.
141. Prasannarong, M., Santos, F. R. and Henriksen, E. J. (2012) ANG-(1-7) reduces ANG II-induced insulin resistance by enhancing Akt phosphorylation via a Mas receptor-dependent mechanism in rat skeletal muscle. Biochem. Biophys. Res. Commun. 426, 369-373.
142. Olivares-Reyes, J. A., Arellano-Plancarte, A. and Ramon Castillo-Hernandez, J. (2009) Angiotensin II and the development of insulin resistance: implications for diabetes. Mol. Cell. Endocrinol. 302, 128-139.
143. Huisamen, B., Pêrel, S. J., Friedrich, S. O., Salie, R., Strijdom, H. and Lochner, A. (2011) ANG II type I receptor antagonism improved nitric oxide production and enhanced eNOS and PKB/Akt expression in hearts from a rat model of insulin resistance. Mol. Cell. Biochem. 349, 21-31.
144. Nakayama, M., Inoguchi, T., Sonta, T., Maeda, Y., Sasaki, S., Sawada, F., Tsubouchi, H., Sonoda, N., Kobayashi, K., Sumimoto, H. and Nawata, H. (2005) Increased expression of NAD(P)H oxidase in islets of animal models of Type 2 diabetes and its improvement by an AT1 receptor antagonist. Biochem. Biophys. Res. Commun. 332, 927-933.
145. Wei, Y., Sowers, J. R., Clark, S. E., Li, W., Ferrario, C. M. and Stump, C. S. (2008) Angiotensin II-induced skeletal muscle insulin resistance mediated by NF-κB activation via NADPH oxidase Am. J. Physiol. Endocrinol. Metab. 294, E345-E351.
146. Diamond-Stanic, M. K. and Henriksen, E. J. (2010) Direct inhibition by angiotensin II of insulin-dependent glucose transport activity in mammalian skeletal muscle involves a ROS-dependent mechanism. Arch. Physiol. Biochem. 116, 88-95.
147. 2)-sensitive signaling pathways activated by angiotensin II in vascular smooth muscle. cells 273, 15022-15029.
148. Eguchi, S., Dempsey, P. J., Frank, G. D., Motley, E. D. and Inagami, T. (2001) Activation of MAPKs by angiotensin II in vascular smooth muscle cells. Metalloprotease-dependent EGF receptor activation is required for activation of ERK and p38 MAPK but not for JNK. J. Biol. Chem. 276, 7957-7962.
149. Hemi, R., Yochananov, Y., Barhod, E., Kasher-Meron, M., Karasik, A., Tirosh, A. and Kanety, H. (2011) p38 mitogen-activated protein kinase-dependent transactivation of ErbB receptor family: a novel common mechanism for stress-induced IRS-1 serine phosphorylation and insulin resistance. Diabetes 60, 1134-1145.
150. Taniyama, Y., Hitomi, H., Shah, A., Alexander, R. W. and Griendling, K. K. (2005) Mechanisms of reactive oxygen species-dependent downregulation of insulin receptor substrate-1 by angiotensin II. Arterioscler. Thromb. Vasc. Biol. 25, 1142-1147.
151. Izawa, Y., Yoshizumi, M., Fujita, Y., Ali, N., Kanematsu, Y., Ishizawa, K., Tsuchiya, K., Obata, T., Ebina, Y., Tomita, S. and Tamaki, T. (2005) ERK1/2 activation by angiotensin II inhibits insulin-induced glucose uptake in vascular smooth muscle cells. Exp. Cell. Res. 308, 291-299.
152. Motley, E. D., Eguchi, K., Gardner, C., Hicks, A. L., Reynolds, C. M., Frank, G. D., Mifune, M., Ohba, M. and Eguchi, S. (2003) Insulin-induced Akt activation is inhibited by angiotensin II in the vasculature through protein kinase C-α. Hypertension 41, 775-780.
153. Zhu, Z., Zhong, J., Zhu, S., Liu, D., Van Der Giet, M. and Tepel, M. (2002) Angiotensin-(1-7) inhibits angiotensin II-induced signal transduction. J. Cardiovasc. Pharmacol. 40, 693-700.
154. Su, Z., Zimpelmann, J. and Burns, K. D. (2006) Angiotensin-(1-7) inhibits angiotensin II-stimulated phosphorylation of MAP kinases in proximal tubular cells. Kidney Int. 69, 2212-2218.
155. Sampaio, W. O., Henrique de Castro, C., Santos, R. A., Schiffrin, E. L. and Touyz, R. M. (2007) Angiotensin-(1-7) counterregulates angiotensin II signaling in human endothelial cells. Hypertension 50, 1093-1098.
156. Yang, Y. J., Hope, I. D., Ader, M. and Bergman, R. N. (1989) Insulin transport across capillaries is rate limiting for insulin action in dogs. J. Clin. Invest. 84, 1620-1628.
157. Barrett, E., Eggleston, E., Inyard, A., Wang, H., Li, G., Chai, W. and Liu, Z. (2009) The vascular actions of insulin control its delivery to muscle and regulate the rate-limiting step in skeletal muscle insulin action. Diabetologia 52, 752-764.
158. Barrett, E. J., Wang, H., Upchurch, C. T. and Liu, Z. (2011) Insulin regulates its own delivery to skeletal muscle by feed-forward actions on the vasculature. Am. J. Physiol. Endocrinol. Metab. 301, E252-E263.
159. Wang, N., Chai, W., Zhao, L., Tao, L., Cao, W. and Liu, Z. (2013) Losartan increases muscle insulin delivery and rescues insulin's metabolic action during lipid infusion via microvascular recruitment. Am. J. Physiol. Endocrinol. Metab. 304, E538-E545.
160. Marcus, Y., Shefer, G., Sasson, K., Kohen, F., Limor, R., Pappo, O., Nevo, N., Biton, I., Bach, M., Berkutzki, T. et al. (2013) Angiotensin-1-7 as means to prevent the metabolic syndrome: lessons from the fructose-fed rat model. Diabetes 62, 1121-1130.
161. Santos, S. H. S., Felix Braga, J., Guilhen Mario, E., Pôrto, L. C. J., Rodrigues-Machado, M. G., Murari, A., Botion, L. M., Alenina, N., Bader, M. and Santos, R. A. S. (2010) Improved lipid and glucose metabolism in transgenic rats with increased circulating angiotensin-(1-7). Arterioscler. Thromb. Vasc. Biol. 30, 953-961.
162. Bilman, V., Mares-Guia, L., Nadu, A. P., Bader, M., Campagnole-Santos, M. J., Santos, R. A. and Santos, S. H. (2012) Decreased hepatic gluconeogenesis in transgenic rats with increased circulating angiotensin-(1-7). Peptides 37, 247-251.
163. Santos, S. H., Fernandes, L. H., Pereira, C. S, Guimaraes, A. L., de Paula, A. M., Campagnole-Santos, M. J., Alvarez-Leite, J. I., Bader, M. and Santos, R. A (2012) Increased circulating angiotensin-(1-7) protects white adipose tissue against development of a proinflammatory state stimulated by a high-fat diet. Regul. Pept. 178, 64-70.
164. Abuissa, H., Jones, P. G., Marso, S. P. and O'Keefe, Jr, J. H. (2005) Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes. A meta-analysis of randomized clinical trials. J. Am. Coll. Cardiol. 46, 821-826.
165. Padwal, R. and Laupacis, A. (2004) Antihypertensive therapy and incidence of type 2 diabetes. A systematic review. Diabetes Care 27, 247-255.
166. Iwai, M., Nakaoka, H., Senba, I., Kanno, H., Moritani, T. and Horiuchi, M. (2012) Possible involvement of angiotensin-converting enzyme 2 and Mas activation in inhibitory effects of angiotensin II Type 1 receptor blockade on vascular remodeling. Hypertension 60, 137-144.
167. Takeda, M., Yamamoto, K., Takemura, Y., Takeshita, H., Hongyo, K., Kawai, T., Hanasaki-Yamamoto, H., Oguro, R., Takami, Y., Tatara, Y. et al. (2013) Loss of ACE2 exaggerates high-calorie diet-induced insulin resistance by reduction of GLUT4 in mice. Diabetes 62, 223-233.
168. Bindom, S. M., Hans, C. P., Xia, H., Boulares, A. H. and Lazartigues, E. (2010) Angiotensin I-converting enzyme type 2 (ACE2) gene therapy improves glycemic control in diabetic mice. Diabetes 59, 2540-2548.
169. Chhabra, K. H., Xia, H., Pedersen, K. B., Speth, R. C. and Lazartigues, E. (2013) Pancreatic angiotensin-converting enzyme 2 improves glycemia in angiotensin II-infused mice. Am. J. Physiol. Endocrinol. Metab. 304, E874-E884.
170. Park, S., Bivona, B. J., Ford, Jr, S. M., Hiroyuki Kobori, S. X., de Garavilla, L. and Harrison-Bernard, L. M. (2013) Direct evidence for intrarenal chymase-dependent angiotensin II formation on the diabetic renal microvasculature. Hypertension 61, 465-471.
171. Santos, S. H., Fernandes, L. R., Mario, E. G., Ferreira, A. V., Pôrto, L. C., Alvarez-Leite, J. I., Botion, L. M., Bader, M., Alenina, N. and Santos, R. A. (2008) Mas deficiency in FVB/N mice produces marked changes in lipid and glycemic metabolism. Diabetes 57, 340-347.
172. Mario, E. G., Santos, S. H., Ferreira, A. V., Bader, M., Santos, R. A. and Botion, L. M. (2012) Angiotensin-(1-7) Masreceptor deficiency decreases peroxisome proliferatoractivated receptor γ expression in adipocytes. Peptides 33, 174-177.
173. Benter, I. F., Yousif, M. H. M, Cojocel, C., Al-Maghrebi, M. and Diz, D. I. (2007) Angiotensin-(1-7) prevents diabetes-induced cardiovascular dysfunction. Am. J. Physiol. Heart. Circ. Physiol. 292, H666-H672.
174. Singh, K., Singh, T. and Sharma, P. L. (2011) Beneficial effects of angiotensin-(1-7) in diabetic rats with cardiomyopathy. Ther. Adv. Cardiovasc. Dis. 5, 159-167.
175. Ebermann, L., Spillmann, F., Sidiropoulos, M., Escher, F., Heringer-Walther, S., Schultheiss, H. P., Tschope, C. and Walther, T. (2008) The angiotensin-(1-7) receptor agonist AVE0991 is cardioprotective in diabetic rats. Eur. J. Pharmacol. 590, 276-280.
176. Fraga-Silva, R. A., Costa-Fraga, F. P., Murça, T. M., Moraes, P. L., Martins Lima, A., Lautner, R. Q., Castro, C. H., Soares, C. M. A., Borges, C. L., Nadu, A. P. et al. (2013) Angiotensinconverting enzyme 2 activation improves endothelial function. Hypertension 61, 1233-1238.
177. Akhtar, S., Yousif, M. H., Dhaunsi, G. S., Chandrasekhar, B., Al-Farsi, O. and Benter, I. F. (2012) Angiotensin-(1-7) inhibits epidermal growth factor receptor transactivation via a Mas receptor-dependent pathway. Br. J. Pharmacol. 165, 1390-1400.
178. Patel, V. B., Bodiga, S., Basu, R., Das Subhash, K., Wang, W., Wang, Z., Lo, J., Grant, M. B., JiuChang, Z., Zamaneh, K. and Oudit, G. Y. (2012) Loss of angiotensin-converting enzyme-2 exacerbates diabetic cardiovascular complications and leads to systolic and vascular dysfunction: a critical role of the angiotensin II/AT1 receptor axis. Circ. Res. 110, 1322-1335.
179. Giani, J. F., Muñoz, M. C., Mayer, M. A., Veiras, L. C., Arranz, C., Taira, C. A., Turyn, D., Toblli, J. E. and Dominici, F. P. (2010) Angiotensin-(1-7) improves cardiac remodeling and inhibits growth-promoting pathways in the heart of fructose-fed rats. Am. J. Physiol. Heart Circ. Physiol. 298, H1003-H1013.
180. Benter, I. F., Yousif, M. H., Dhaunsi, G. S., Kaur, J., Chappell, M. C. and Diz, D. I. (2008) Angiotensin-(1-7) prevents activation of NADPH oxidase and renal vascular dysfunction in diabetic hypertensive rats. Am. J. Nephrol. 28, 25-33.
181. Singh, T., Singh, K. and Sharma, P. L. (2010) Ameliorative potential of angiotensin-1-7/Mas receptor axis in streptozotocin-induced diabetic nephropathy in rats. Methods Find. Exp. Clin. Pharmacol. 32, 19-25.
182. y/Ta mice. Am. J. Physiol. Renal Physiol. 300, F1271-F1282.
183. Dhaunsi, G. S., Yousif, M. H., Akhtar, S., Chappell, M. C., Diz, D. I. and Benter, I. F. (2010) Angiotensin-(1-7) prevents diabetes-induced attenuation in PPAR-γ and catalase activities. Eur. J. Pharmacol. 638, 108-114.
184. Giani, J. F., Burghi, V., Veiras, L. C., Tomat, A., Muñoz, M. C., Cao, G., Turyn, D., Toblli, J. E. and Dominici, F. P. (2012) Angiotensin-(1-7) attenuates diabetic nephropathy in Zucker diabetic fatty rats. Am. J. Physiol. Renal Physiol. 302, F1606-F1615.
185. Shiota, A., Yamamoto, K., Ohishi, M., Tatara, Y., Ohnishi, M., Maekawa, Y., Iwamoto, Y., Takeda, M. and Rakugi, H. (2010) Loss of ACE2 accelerates time-dependent glomerular and tubulointerstitial damage in streptozotocin-induced diabetic mice. Hypertens. Res. 33, 298-307.
186. Nadarajah, R., Milagres, R., Dilauro, M., Gutsol, A., Xiao, F., Zimpelmann, J., Kennedy, C., Wysocki, J., Batlle, D. and Burns, K. D. (2012) Podocyte-specific overexpression of human angiotensin-converting enzyme 2 attenuates diabetic nephropathy in mice. Kidney Int. 82, 292-303.
187. Yousif, M. H., Dhaunsi, G. S., Makki, B. M., Qabazard, B. A., Akhtar, S. and Benter, I. F. (2012) Characterization of angiotensin-(1-7) effects on the cardiovascular system in an experimental model of type-1 diabetes. Pharmacol. Res. 66, 269-275.
188. Verma, A., Shan, Z., Lei, B., Yuan, L., Liu, X., Nakagawa, T., Grant, M. B., Lewin, A. S., Hauswirth, W. W., Raizada, M. K. and Li, Q. (2012) ACE2 and Ang-(1-7) confer protection against development of diabetic retinopathy. Mol. Ther. 20, 28-36.
189. Rodgers, K., Verco, S., Bolton, L. and Dizerega, G. (2011) Accelerated healing of diabetic wounds by NorLeu(3)- angiotensin (1-7). Expert Opin. Investig. Drugs 20, 1575-1581.
190. Lula, I., Denadai, A. L., Resende, J. M., Sousa, F. B., Lima, G. F., Pilo-Veloso, D., Heine, T., Duarte, H. A., Santos, R. A. S. and Sinisterra, R. D. (2007) Study of angiotensin-(1-7) vasoactive peptide and its β-cyclodextrin inclusion complexes: complete sequence-specific NMR assigments and structural studies. Peptides 28, 2199-2210.
191. Santos, S. H., Andrade, J. M., Fernandes, L. R., Sinisterra, R. D., Sousa, F. B., Feltenberger, J. D., Alvarez-Leite, J. I. and Santos, R. A. (2013) Oral angiotensin-(1-7) prevented obesity and hepatic inflammation by inhibition of resistin/TLR4/ MAPK/NF-κB in rats fed with high-fat diet. Peptides 46, 47-52.
192. Feltenberger, J. D., Andrade, J. M., Paraíso, A., Barros, L. O., Filho, A. B., Sinisterra, R. D., Sousa, F. B., Guimarães, A. L., de Paula, A. M., Campagnole-Santos, M. J. et al. (2013) Oral formulation of angiotensin-(1-7) improves lipid metabolism and rrevents high-fat diet-induced hepatic steatosis and inflammation in mice. Hypertension 62, 324-330.